updated 9/7/2010 6:45:54 AM ET 2010-09-07T10:45:54

DALLAS, Sept. 3, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Orexigen Therapeutics Inc. (Nasdaq:OREX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/OREX

Orexigen Therapeutics Inc. (OREX) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its combination product candidates targeted for obesity are Contrave which has completed phase 3 clinical trials, and Empatic, which has completed phase 2 clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release (SR) formulation. Bupropion is a prescribed antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. Empatic is a combination of bupropion SR and zonisamide SR. Zonisamide, in a release formulation, was approved in the United States for the adjunctive treatment of partial seizures, a form of epilepsy. These product candidates regulate appetite and energy expenditure through the central nervous system (CNS). 

Message Board Search for OREX: http://www.boardcentral.com/boards/OREX

In the report, the analyst notes:

"OREX recently announced financial results for the second quarter of 2010.  For the quarter ended June 30, 2010, OREX reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.  

"OREX said it sold the North American marketing rights for its experimental weight loss drug to Japan's Takeda Pharmaceutical Co. Ltd. in a deal that could be worth more than $1 billion, sending its shares up 28%. OREX is one of three U.S. companies that is trying to get approval for the first new diet drug in a decade, along with Arena Pharmaceuticals Inc. and Vivus Inc."

To read the entire report visit: www.microstockprofit.com/lp/OREX

See what investors are saying about OREX at http://www.stockhideout.com

Get breaking news on OREX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.95%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com